Pati

Monitoring Patient Glucose Levels: New Advances in software make it easier

Monitoring patient glucose levels and determining the response to intervention is critical when working with diabetic clients. The benefit of doing so in improved outcomes for both type 1 and type 2 diabetes has been clearly established by clinical trials conducted in both the U.S. and the UK1. Self- monitoring by patients of glucose levels, and the data provided is especially important for p...

Managing Preanalytical Processes for Patient Safety

Contributing Editor Positive patient identification (ID) is a major put by healthcare accrediting bodies for the past few years. Until recently, the costs associated with hardware and software were beyond the reach of the average hospital or laboratory. Today there are multiple vendors with devices that can be integra...

Hematology Analyzers Simple, Sophisticated Technology Serving All Patients

Some form of electronic hematology analyzer is found at the center of most clinical laboratories. A blood cell count is usually the first screening test used to assess general health, rule out anemia or infection, and monitor cancer patients during the course of chemotherapy. It is difficult to imagine medical...

Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing

C-reactive protein (CRP) is an acute-phase protein that has long been recognized as a marker of systemic inflammation. CRP measurement can complement a range of diagnostic markers to monitor infection and direct treatment. However, as economic rationalization...

Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis

- Multinational Phase III Study Meets Primary Endpoint inRheumatoid Arthritis Patients Who Failed to Respond to Anti-tumorNecrosis Factor Treatments - NUTLEY, N.J., July 10, 2007 /PRNewswire/ -- Roche todayannounced that results from the Actemra Radiate (RheumAtoiDArthritIs Study in Anti-TNF FailurEs) trial successfully met itsprimary endpoint in patients with moderate to severe rheumatoi...

AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease

PORTLAND, Ore.--(BUSINESS WIRE)--Jul 10, 2007 - AVI BioPharma, Inc.(Nasdaq:AVII) announced today that its partner Cook Medical hascompleted target patient enrollment and released six-monthfollow-up data from a Phase II clinical trial known as Appraisal.The trial, currently being held in Germany, was designed to studythe effect of the Neugene(R) antisense drug Resten-MP(TM), whenused in conj...

International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis

- ENDORSE Global Findings Highlight the Need to UrgentlyImplement Hospital-Wide Strategies to Optimize VTE Management:Systematically Assess Patient Risk for VTE and Provide Appropriateprophylaxis to Prevent VTE Venous thromboembolism (VTE) risk is high among hospitalpatients and most of these at-risk patients are not pro...

NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product

EAST WINDSOR, N.J.--(BUSINESS WIRE)--July 9, 2007 - NexMed, Inc.(NASDAQ: NEXM), a developer of innovative transdermal treatmentsbased on the NexACT(R) drug delivery technology, today announcedthat Novartis Pharma AG has completed patient enrollment for PhaseIII clinical trials for NM100060, a topical treatment foronychomycosis (nail fungus). Pursuant to the terms of the licensingagreement w...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

Rivaroxaban, a New Oral, Once-Daily Direct Factor Xa Inhibitor,Shows a Significant Reduction in Deep Vein Thrombosis and PulmonaryEmbolism Compared with Enoxaparin with Similarly Low BleedingRates GENEVA, July 8, 2007 - Late-breaking Phase III clinical trialdata presented today at the XXI International Society on Thrombosisand Haemostasis (ISTH) Congress demonstrate that once-daily...

New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility

EXCLAIM is the First International Study to Show That ExtendedThromboprophylaxis Reduces VTE Risk in Acutely-ill Medical PatientsWith a Statistically Significant 44% PARIS, July 8, 2007 /PRNewswire-FirstCall/ --Sanofi-aventisannounced today the results of the EXCLAIM (EXtended CLinicalprophylaxis in Acutely Ill Medical patients) study, which showedthe benefit of extended prophylaxi...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

GENEVA--(BUSINESS WIRE)--Jul 8, 2007 - Late-breaking Phase IIIclinical trial data presented today at the XXI InternationalSociety on Thrombosis and Haemostasis (ISTH) Congress demonstratethat once-daily rivaroxaban achieved superior efficacy in theprevention of venous thromboembolism (VTE) in patients undergoingknee replacement surgery in a head-to-head comparison withenoxaparin, the curren...

Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea

CAMBRIDGE, Mass., July 06, 2007 /PRNewswire-FirstCall/ --Genzyme Corp. announced top-line data today from the first of twoPhase 3 clinical studies to assess the safety and efficacy oftolevamer liquid, an investigational, non-antibiotic, polymertherapy for patients with Clostridium difficile associated diarrhea(CDAD). The second Phase 3 study of tolevamer liquid is fullyenrolled and resul...

TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials

Data Published in The Lancet on TMC125, an Investigational NNRTIfrom Tibotec YARDLEY, Pa., July 05, 2007 /PRNewswire/ -- Data from twoongoing Phase 3 studies (DUET-1 and DUET-2) showed significantlymore HIV-1 adult patients with documented non-nucleoside reversetranscriptase inhibitor (NNRTI) and protease inhibitor (PI)resistance reached an undetectable viral load (defined as achievingco...

Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine

- Phase II Results Published in the Journal of Clinical Oncology - NEW YORK, July 06, 2007 /PRNewswire-FirstCall/ -- Results from aPhase II study - which will be published in the August 10, 2007issue of the Journal of Clinical Oncology (JCO) and are nowavailable as an Early Release Article at <a target="_blank" href="http://www.jco.org/">www.jco.org - demonstrate thatixabepilone, a Br...

Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis

SCHLIEREN (Zurich), Switzerland, July 3, 2007 - Cytos BiotechnologyAG (SWX:CYTN) announced today results from a phase IIa study withCYT003-QbG10 in atopic dermatitis. CYT003-QbG10 is animmunotherapeutic product candidate currently in development forthe treatment of allergic diseases. The present study aimed toassess safety, tolerability and exploratory efficacy of the productcandidate in a...

Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients

PHILADELPHIA, July 3, 2007-- – The appearance of arash in cancer patients treated with erlotinib (Tarceva) isstrongly associated with longer survival, according to researchersfrom the drug’s developer, OSI Pharmaceuticals, Inc. This isnot the first time that rash has been associated with a survivaladvantage with EGFR inhibitors – a class of drugs whichincludes erlotinib...

Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia

Data presented at the 11th International Myeloma Workshop held inKos, Greece demonstrates clinical activity of perifosine incombination with bortezomib, dexamethasone and lenalidomide plusdexamethasone, in patients with relapsed/refractory multiplemyeloma, and as a single agent in patients with relapsed/refractoryWaldenstrom's macroglobulinemia NEW YORK, June 29, 2007 /PRNewswire-FirstCal...

The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients

- Data Presented at the 11th International Myeloma Workshop - NORTH HOLLYWOOD, Calif., and KOS, Greece, June 29, 2007/PRNewswire/ -- The International Myeloma Foundation (IMF) --supporting research and providing education, advocacy and supportfor myeloma patients, families, researchers and physicians -- todaysaid that updated statistics reported at the 11th InternationalMyeloma Workshop i...

Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma

- 100 percent of patients treated with VELCADE, cyclophosphamide,and prednisone alive at one year - KOS, Greece, June 28, 2007 /PRNewswire-FirstCall/ -- MillenniumPharmaceuticals, Inc. today reported on the presentation of resultsfrom clinical trials of VELCADE based therapies that showed highcomplete remission / complete response(1) (CR) rates in previouslytreated multiple myeloma (MM) p...

Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients

-- 100 percent response rate achieved with VELCADE, lenalidomideand dexamethasone KOS, Greece, June 28 /PRNewswire-FirstCall/ -- MillenniumPharmaceuticals, Inc. (Nasdaq: MLNM) today reported on thepresentation of results from four clinical trials of VELCADE basedtherapies that showed consistently high survival and completeremission / complete response(1) (CR) rates in newly diag...

Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness

TARRYTOWN, N.Y. & MADISON, N.J.--(BUSINESS WIRE)--Jun 28, 2007- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) and WyethPharmaceuticals, a division of Wyeth (NYSE: WYE), today announcedpositive results from a three-month open-label extension study ofsubcutaneous methylnaltrexone for the treatment of opioid-inducedconstipation (OIC) in patients with advanced illness. The resultsare sched...

A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients

Final Results from Exploratory Phase IIa Clinical Trial in Type 2Diabetes Patients Announced TORONTO, June 28, 2007 /PRNewswire-FirstCall/ - TransitionTherapeutics Inc. ("Transition") , today announces the results fromits exploratory Phase IIa clinical trial indicating that 4-weeks ofdaily treatments with gastrin-based therapy, E1-I.N.T.(TM), showedsustained reductions in blood glucose co...

An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 25, 2007 - New data from aninvestigational study released at the American Diabetes Association(ADA) 67th Annual Scientific Sessions showed that initialcombination therapy with Januvia(TM) (sitagliptin) and metformindemonstrated significant improvement in markers of beta cellfunction in patients with type 2 diabetes. Pancreatic islet betacell function determines...

Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis

RESEARCH TRIANGLE PARK, N.C. & SHERBROOKE, Quebec--(BUSINESSWIRE)--Jun 26, 2007 - Tranzyme Pharma, a leading biopharmaceuticalcompany developing small molecule drugs for the treatment ofgastrointestinal and metabolic diseases, today announced positiveresults for its novel ghrelin agonist, TZP-101, in acceleratinggastric emptying in diabetic patients with gastroparesis. The datafrom a pi...

New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir

Minimal Weight Change Reported Unlike What Is Commonly Seen InInsulin Therapy CHICAGO, June 24, 2007 – Novo Nordisk today announcedresults of a new study that further demonstrated the safety andefficacy of insulin Levemir® (insulin detemir [rDNA origin]injection). Patients with Type 2 diabetes were able to adjusttheir own dosage of Levemir® and achieve improvements i...

Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke

CHICAGO--(BUSINESS WIRE)--Jun 25, 2007 - Pfizer announced todaythat Lipitor (atorvastatin calcium) Tablets 80 mg reduced the riskof stroke, coronary heart disease events and major coronary eventsin type 2 diabetes patients who had no known coronary heart diseasebut who had experienced a recent stroke or mini-stroke, comparedwith placebo. The results are from a new analysis of the landmarkSt...

Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target

New study demonstrates 75% of patients receiving highest doseachieves A1c with no associated hypoglycemia CHICAGO, June 25, 2007 /PRNewswire-FirstCall/ -- According tofindings presented today at the 67th Scientific Sessions of theAmerican Diabetes Association (ADA) in Chicago, Illinois, theinvestigational treatment liraglutide, a once- daily dose of humanGLP-1 analog under development by...

Second Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint

FOSTER CITY, Calif.--(BUSINESS WIRE)--June 25, 2007--GileadSciences, Inc. (Nasdaq:GILD) today announced that Study 103, aPhase III clinical trial evaluating the company's once-dailyanti-HIV drug Viread(R) (tenofovir disoproxil fumarate or tenofovirDF) 300 mg as a potential treatment for chronic hepatitis B virus(HBV) infection, met its primary efficacy endpoint. The data showthat Viread...

Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes

Data Also Support Drug's Efficacy at Improving Glycemic Control andReducing Diabetic Cardiovascular Complications CHICAGO, Ill., June 23, 2007 /PRNewswire/ -- VeroScience, LLC,in conjunction with its commercialization partner S2 Therapeutics,Inc., reported today the results of its Phase IIIb clinical trialsupporting the overall and cardiovascular safety of Cycloset(TM) (Aquick release for...

Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 23, 2007 - Late breaking datapresented at the American Diabetes Association (ADA) 67th AnnualScientific Sessions showed that, when used investigationally asinitial therapy, JANUVIA(TM) (sitagliptin) in combination withmetformin provided significant glycemic improvement and wasgenerally well tolerated over 54 weeks in patients with type 2diabetes. Additional new...

New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes

* Significant blood sugar reductions seen across range ofpatient populations, including varied ethnic groups, the elderly,and those at high risk of developing diabetes * Galvus lowers blood sugar when added to a sulfonylurea,reinforcing efficacy in combination with commonly used diabetesmedicines * Data confirm good tolerability in humans with studies showingincidence of sid...

New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir

Minimal Weight Change Reported Unlike What Is Commonly Seen InInsulin Therapy CHICAGO, June 25, 2007 /PRNewswire-FirstCall/ -- Novo Nordisktoday announced results of a new study that further demonstratedthe safety and efficacy of insulin Levemir(R) (insulin detemir[rDNA origin] injection). Patients with type 2 diabetes were ableto adjust their own dosage of Levemir(R) and achieve improvem...

Second Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - GileadSciences, Inc. (Nasdaq:GILD) today announced that Study 103, aPhase III clinical trial evaluating the company's once-dailyanti-HIV drug Viread(R) (tenofovir disoproxil fumarate or tenofovirDF) 300 mg as a potential treatment for chronic hepatitis B virus(HBV) infection, met its primary efficacy endpoint. The data showthat Viread is...

Elixir Pharmaceuticals Announces Clinical Data at American Diabetes Association Conference Highlighting Ability of Glufast to Maintain Glycemic Control in Patients with Type 2 Diabetes

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 25, 2007 - ElixirPharmaceuticals, Inc., announced today the publication of clinicaldata highlighting the ability of Glufast(R) (mitiglinide calciumhydrate) monotherapy, or combination therapy with metformin, tomanage glucose surges before and after meals. The data werepublished in the Abstract Book for the American DiabetesAssociation 67th Annual Scien...

Infertile Voice Supports Stem Cell Research: RESOLVE Calls for Patient Options in Using Frozen Embryos

New survey shows more than half of infertile couples willing todonate unused embryos for stem cell research BETHESDA, Md., June 20, 2007 /PRNewswire/ -- RESOLVE: TheNational Infertility Association issued the following statementtoday, in anticipation of President Bush's veto of federallegislation that would loosen current limitations on stem cellresearch: "President Bush is choosin...

Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinson's Disease

FORT LEE, N.J.--(BUSINESS WIRE)--Jun 21, 2007 - Neurologix, Inc.(OTCBB:NRGX) today announced the publication in the June 23 issueof the journal The Lancet of positive results from the first evergene therapy trial for Parkinson's disease and the first report ofdirect gene transfer into a patient's own brain cells for any adultneurodegenerative disease. The open label Phase 1 study, conduct...

Nationwide MRSA Prevalence Study to Demonstrate Full Scope of 'Superbug' Threat Facing U.S. Healthcare Facilities and Patients

Broadest, Most Comprehensive Survey Provides New Benchmark on MRSAin Healthcare Facilities WASHINGTON, June 21, 2007 /PRNewswire-USNewswire/ -- Thefollowing was released today by APIC: WHAT: -- First nationwide study of the prevalence of Methicillin-resistant Staphylococcus aureus (MRSA), a virulent multi-drug resistant organism, in U.S. healthcare facilit...

Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection

SAN DIEGO, June 20, 2007 /PRNewswire-FirstCall/ -- AnadysPharmaceuticals, Inc. , a biopharmaceutical company committed tothe discovery, development and commercialization of novel medicinesfor the treatment of hepatitis and cancer, announced today that ithas nominated ANA598 as a candidate for clinical development as anorally-administered direct antiviral for the treatment of chronichepat...

New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes

RIDGEFIELD, Conn., June 18, 2007 /PRNewswire/ -- Today, resultsfrom AMADEO*, one of a series of studies comparing two angiotensinreceptor blockers (ARBs) in hypertensive patients with diabeticnephropathy, were presented at the 17th annual European Meeting onHypertension in Milan, Italy. The randomized, double-blind, forced titration, parallel group,multicenter study included 860 hy...

New Study Shows That telmisartan has Greater Renoprotective Potential Thanlosartan in Hypertensive Patients With Type 2 Diabetes

MILAN, Italy, June 15 /CNW/ - Today AMADEO, one of thefirst studies to compare the protective potential of twoangiotensin receptor blockers in hypertensive patients withdiabetic nephropathy, was presented at the European Societyof Hypertension, Milan. The results from this study show that telmisartan reduces proteinuria to a significantly greater extentthan losartan.(1)...